Brief: Biomerica Announces Positive Topline Results From Endpoint Clinical Trial Of Its Infoods IBS Treatment

Biomerica

08/02/2022 12:27

Feb 8 (Reuters) - Biomerica Inc  BMRA.O :
    * BIOMERICA ANNOUNCES POSITIVE TOPLINE RESULTS FROM THE
ENDPOINT
CLINICAL TRIAL OF ITS INFOODS® IBS TREATMENT FOR PATIENTS WITH
IRRITABLE BOWEL SYNDROME
    * BIOMERICA INC - PLANS TO MEET WITH FDA TO REVIEW THESE
RESULTS
AND FINALIZE A PIVOTAL TRIAL FOR FDA CLEARANCE
    * BIOMERICA-MULTIPLE ENDPOINTS SHOW STATISTICALLY
SIGNIFICANT
IMPROVEMENTS, INDICATING ELIMINATION OF SPECIFIC FOODS MAY
REDUCE SYMPTOMS OF IBS IN ALL SUBTYPES
    * BIOMERICA - GREATEST CLINICAL IMPROVEMENTS, INCLUDING BUT
NOT
LIMITED TO PAIN AND BLOATING, WERE SEEN IN PATIENTS DIAGNOSED
WITH IBS-MIXED AND IBS-CONSTIPATION

Source text for Eikon:  ID:nGNX9tGPXT 
Further company coverage:  BMRA.O 

 ((Reuters.Briefs@thomsonreuters.com;))